- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06885203
Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)
The goal of this research study is to learn about the effects of the BBCSI course on the quality of life of Black breast cancer survivors.
A community-based and peer-led Black Breast Cancer Survivor's Intervention (BBCSI) course has been developed to help improve the quality of life of Black breast cancer survivors.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objectives:
Develop a prototype of the BBCSI curriculum and assess satisfaction of the intervention.
Determine the preliminary efficacy of the BBCSI.
Evaluate fidelity, feasibility, acceptability, barriers, and facilitators of the BBCSI.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dede Teteh-Brooks, DRPH
- Phone Number: 713-563-3493
- Email: dkteteh@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas M. D. Anderson Cancer Center
-
Contact:
- Dede Teteh-Brooks, DRPH
- Phone Number: 713-563-3493
- Email: dkteteh@mdanderson.org
-
Principal Investigator:
- Dede Teteh-Brooks, DRPH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Study Population
Description
Inclusion Criteria:
Master Trainers:
To be eligible to participate in this study, an individual must meet all the following criteria:
- Adult women aged 18 years and older
- Histologically confirmed stage 0-III breast cancer
- No evidence of metastatic disease
- Self-identify as Black
- Able to communicate in English
Participants:
To be eligible to participate in this study, an individual must meet all the following criteria:
- Adult women aged 18 years and older
- Histologically confirmed stage 0-III breast cancer
- No evidence of metastatic disease
- Within four-years of diagnosis
- Self-identify as Black
- Able to communicate in English
Community Interventionists:
To be eligible to participate in this study, an individual must meet all the following criteria:
- Adult women aged 18 years and older
- Histologically confirmed stage 0-III breast cancer
- No evidence of metastatic disease
- Self-identify as Black
- Former study participants that have completed the intervention
- Able to communicate in English
General Exclusion Criteria:
- Men or woman below 18 years of age
- Does not have a histologically confirmed breast cancer
- There's evidence of metastatic disease
- Does not self-identify as Black
- Unable to communicate in English
Additional Exclusion Criteria - Participants 1. More than four years of diagnosis
Additional Exclusion Criteria - Community Interventionists
1. Has not previously participated in and completed the study intervention as a participant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Immediate Intervention Group
Participants will be recruited through our Community Based Organizations (CBOs) and other community collaborator networks.
|
Participants will complete the BBCSI course (1-hour virtual sessions every week for 6 weeks), answer questionnaires before and after the course, and provide urine samples.
|
|
Experimental: Wait-List (start in week 7)
Participants will be recruited through our Community Based Organizations (CBOs) and other community collaborator networks.
|
Participants will complete the BBCSI course (1-hour virtual sessions every week for 6 weeks), answer questionnaires before and after the course, and provide urine samples.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety and Adverse Events (AEs)
Time Frame: Time Frame: Through study completion; an average of 1 year
|
Safety and Adverse Events (AEs)
|
Time Frame: Through study completion; an average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dede Teteh-Brooks, DRPH, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024-1563
- NCI-2025-02122 (Other Identifier: NCI-CTRP Clinical Trials Registry)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Black Breast Cancer Survivor's Intervention
-
Unilever R&DLotus Labs Pvt. Ltd, Bangalore, India; Clumax Diagnostics, Bangalore, India; Quipu...Completed
-
Herlev and Gentofte HospitalUniversity of CopenhagenCompleted
-
Federal University of MaranhaoActive, not recruitingBreast Cancer | Breast - Female | Breast Cancer FemalesBrazil
-
Royal Marsden NHS Foundation TrustNational Institute for Health Research, United KingdomActive, not recruitingBreast Cancer | Lifestyle Risk ReductionUnited Kingdom
-
Northeastern UniversityAmerican Physical Therapy AssociationCompletedBreast Cancer
-
Federal University of MaranhaoNot yet recruitingBreast Cancer | Breasts - Female | Breast Cancer in Women
-
Istituti Clinici Scientifici Maugeri SpARecruiting
-
Icahn School of Medicine at Mount SinaiNational Cancer Institute (NCI); Northwestern University Feinberg School of... and other collaboratorsCompletedDiabetes | Breast CancerUnited States
-
Ankara Etlik City HospitalRecruitingBreast Surgery | Pain, Acute | Breast Cancer Surgery | Pain, Chronic | MastectomyTurkey
-
Washington University School of MedicineNational Institute on Minority Health and Health Disparities (NIMHD)CompletedOncology | Breast Cancer Screening | Mammography | Preventative MedicineUnited States